Introduction. Recurrent vulvovaginal candidiasis is defined as having three to four episodes per year and causes substantial suffering. Little is known about the mechanisms leading to relapses in otherwise healthy women. Nitric oxide is part of the nonspecific host defense and is increased during inflammation. Nitric oxide levels were measured and the expression of inducible nitric oxide synthase was analyzed in the vagina during an acute episode of recurrent vulvovaginal candidiasis and after treatment with fluconazole. Material and methods. Twenty-eight women with symptoms of recurrent vulvovaginal candidiasis were enrolled together with 31 healthy controls. Nitric oxide was measured with an air-filled 25-mL silicon catheter balloon incubated in the vagina for five minutes and then analyzed by chemiluminescence technique. Vaginal biopsies were analyzed for the expression of inducible nitric oxide synthase. Symptoms and clinical findings were surveyed using a scoring system. The measurements and biopsies were repeated in patients after six weeks of fluconazole treatment. Results. Nitric oxide levels were increased during acute infection (median 352 ppb) compared with controls (median 6 ppb), p < 0.0001. The levels decreased after treatment (median 18 ppb) but were still higher than in controls. Increased expression of inducible nitric oxide synthase was observed in the epithelial basal layer in patients before and after treatment compared with controls. Before treatment, there were positive correlations between nitric oxide and symptom (r s = 0.644) and examination scores (r s = 0.677), p < 0.001. Conclusions. Nitric oxide is significantly elevated in patients with recurrent vulvovaginal candidiasis during acute episodes of infection and decreases after antifungal treatment. The results illustrate the pronounced inflammatory response in recurrent vulvovaginal candidiasis correlating to symptoms of pain and discomfort.
Introduction
Vulvovaginal candidiasis (VVC) in young women is a common cause of gynecological visits. Sporadic infections affect 75% of all women of reproductive age, and 5-8% suffer from recurrent vulvovaginal candidiasis (RVVC), defined as having three or four episodes per year. The major symptoms are pruritus, vaginal discharge, soreness and dyspareunia (1, 2) . The high recurrence rate of RVVC has a severe impact on quality of life and the repeated inflammatory tissue response is a plausible trigger for chronic vulvar pain conditions which may develop over time (3, 4) .
Candida albicans is a commensal fungal organism present in the reproductive tract in 20-30% of healthy asymptomatic women and is responsible for the majority of both VVC and RVVC (2, 5) . Most of the C. albicans strains are susceptible to available anti-mycotic agents and true resistance of isolates is rare (6) (7) (8) . Known risk factors for Candida infections are diabetes, pregnancy and immunosuppression; however, the mechanisms leading to relapses in otherwise healthy individuals are not fully clarified (9, 10) . A combination of altered local immune response and specific virulence factors of the pathogenic Candida species might be responsible for the recurrent infections along with host genetic factors (2) . Most women with RVVC display humoral and cell-mediated immune responses to C. albicans (10) (11) (12) . However, an impaired or altered vaginal innate immune response predisposing to RVVC has been suggested (5, 11) .
Nitric oxide (NO) is part of the innate immunity. It is a short-lived, biologically active free radical gas involved in numerous physiological processes, and it has cytotoxic effects against microorganisms and tumor cells (13) . NO is synthesized by inducible nitric oxide synthase (iNOS), which is up-regulated during inflammation (14, 15) . Previous studies have shown that the release of NO is greatly increased during inflammatory conditions such as asthma and colitis and that the amount of NO can be used for monitoring the grade of inflammation in affected organs (16) (17) (18) . Levels of vaginal NO gas have previously been measured in unspecific vaginitis (19) .
In this study we analyzed levels of NO in the vagina during an acute episode of vulvovaginal candidiasis in patients suffering from RVVC. NO levels were measured before and after antifungal treatment, and were correlated to symptoms and clinical findings. We also investigated the expression of iNOS in vaginal biopsies before and after treatment.
Material and methods
Women with a history of RVVC were invited for a recruitment visit at the vulvar outpatient clinic at Danderyd Hospital, Stockholm, Sweden, during an acute episode of vulvovaginal candidiasis. Inclusion criteria were age 18-40 years, three to four self-reported Candida infections the last year, symptoms of an acute Candida infection and positive culture for C. albicans. Fifty-eight women came for a recruitment visit, but only 28 women, mean age 30 years (range 20-40), fulfilled the inclusion criteria ( Figure 1 ). Forty-seven healthy women with no history of RVVC were invited as possible control subjects. Of these, 31 women, mean age 26 years (range 19-40), were included. Exclusion criteria for both patients and controls were severe illness, pregnancy, and other genital infections such as Chlamydia trachomatis, bacterial vaginosis and other fungal species than C. albicans in cultures ( Figure 1 ). Additional exclusion criteria for all participants were vaginal treatments of any kind, vaginal intercourse in the last 24 h, vaginal douching and ongoing menstruation as well as current antibiotic treatment or other medications that may influence the immune system. The patients came for a second study visit after completing treatment with oral fluconazole 50 mg per day for one week followed by oral fluconazole 150 mg a week for another five consecutive weeks. At the second visit, the same protocol was used. The controls only came for one visit and had not used any anti-fungal treatments prior to the examination. 
Key Message
Vaginal nitric oxide is greatly increased during episodes of recurrent vulvovaginal candidiasis compared with post treatment and healthy controls. Levels of nitric oxide illustrate the inflammatory tissue response corresponding to symptoms and clinical findings.
All participants completed a standardized questionnaire on present clinical symptoms, medical and reproductive history including contraceptive use and lifestyle factors. For identification of C. albicans, vaginal swabs were cultured on CHROMagar and typical colonies were further identified by latex surface antigen agglutination tests at Clinical Microbiology, Karolinska University Hospital, Stockholm, Sweden.
Measurements of vaginal NO levels were performed before the gynecological examination, since manipulation of tissue may increase the levels of NO metabolites, probably due to mechanical provocation (20) . NO levels were measured using a small all-silicon catheter. The catheter balloon was placed in the vagina and filled with 25 mL of room air. After five minutes of incubation, the air was aspirated into a syringe and directly injected into a chemiluminescence analyzer (CLD 77 AM, Eco Physics, D€ urnten, Switzerland) for measurement of NO levels as parts per billion (ppb). The level of NO in the ambient air was measured and subtracted from the NO levels measured in the vagina.
A careful vulvovaginal examination was made with inspection of the vulva and the vagina. Microscopy of wet mount was carried out and specimens for fungal culture and chlamydia polymerase chain reaction were collected. Amsel's criteria were used for exclusion of bacterial vaginosis (vaginal pH >4.5, positive whiff test, homogeneous vaginal discharge and presence of clue cells) (21) .
An examination score was created based on positive clinical findings of vaginal erythema, pathological discharge, dry vulvar skin, fissures and visible hyphae in wet mount, each finding generating one point each (0-5). A symptom score was created in the same way according to the woman's present symptoms of discharge, pruritus, dryness, soreness and pain (0-5).
A vaginal forceps biopsy of 3 mm was obtained after injection with 2 mL of the local anesthetic lidocaine, approximately 3 cm from the vaginal opening. The biopsy was fixed in 4% paraformaldehyde at 4°C for 24 h, then placed in 70% ethanol and thereafter paraffin embedded. Sections were cut at 4 lm and mounted onto glass slides. Immuno-staining for iNOS was manually performed using an EnVision ™ Peroxidase/DAB Detection System kit (Rabbit/Mouse K5007; Dako Products, Agilent Technologies, Santa Clara, CA, USA) according to instructions provided by the manufacturer. Briefly, endogenous peroxidase activity was blocked with 0.3% hydrogen peroxide for 10 min, followed by a blocking step in Dako Protein Block Serum Free solution (X0909) for an additional 10 min. Tissue sections were incubated with a primary rabbit polyclonal antibody NO-53 (1:7000; kind gift from John L. Humes, Merck, USA) directed against a human 6-amino acid C-terminal iNOS peptide for 1 h, followed by incubation with a rabbit polymer/HRP-linked secondary antibody for 30 min. 3,3 0 -Diaminobenzidine (DAB) was applied for 10 min to detect immune-reactivity. Tissue sections were subsequently counterstained with Mayer's hematoxylin, dehydrated and mounted with Pertex (HistoLab, Gothenburg, Sweden). The specificity of the immune-staining was confirmed by lack of staining after omitting the primary antibody. Staining for NADPH-d or iNOS was performed simultaneously on all sections to avoid variability in staining intensity. A semi-quantification of the general iNOS staining was defined as absent = 0, mild = 1, moderate = 2 or intensive = 3 by two independent investigators blinded to the protocol, using a Zeiss Axiophot microscope.
The study was approved by the regional ethics committee in Stockholm (2009/2:8, 2009-10-14). All women received written and oral information about the purpose and conduct of the study and written consent was obtained from all participants.
Statistical analyses
Data were analyzed using IBM SPSS Statistics 22 (IBM Corp., Armonk, NY, USA). For comparison of clinical characteristics and iNOS expression between patients and controls Student's t-test and Fisher's exact test were used as appropriate. The Mann-Whitney U-test was used for comparing NO levels between patients and controls, and the Wilcoxon signed rank test for comparing NO levels in patients before and after treatment. Spearman's rank correlation test was used for correlating vaginal NO levels to the symptom and examination scores, and for correlations between NO and iNOS. The significant level for all tests was <0.05. In the study by Sioutas et al. (19) there were major differences in obtained NO values between patients and controls. Using their data for sample size calculation, the result was eight women in each group. We regarded that number as too low for our secondary outcomes (no previous data available) and therefore decided to include a minimum of 25 patients and controls as a sufficient number of participants (19) .
Results
The characteristics of patients and controls are presented in Table 1 . The patients were older and reported significantly more previous infections of condyloma and bacterial vaginosis, but not other genital infections or cervical dysplasia, compared with the control group. No other differences were observed between the groups.
During acute infection, the median vaginal NO levels were 352 ppb (range 0-6178) in patients compared with a median of 6 ppb (range 0-43) in controls (p < 0.001; Figure 2 ). After completing fluconazole treatment, the NO levels in the patients decreased to a median of 18 ppb (range 0-163; p < 0.001) (Figure 3 ) but were still significantly higher than in the controls (p = 0.003). After treatment, four patients had positive Candida cultures but no symptoms. In a post priori analysis including only patients with negative cultures, the NO levels were still higher in patients after treatment (median 22 ppb, range 0-131) than in the controls (median 6 ppb, range 0-43) (p < 0.005). The NO measurement was well tolerated and no discomfort was reported during the testing procedure. In one patient and two controls the NO levels in the vagina were lower than the concentration in ambient air. In those cases the values were considered outliers and were set to 0 for statistical purposes.
The expression of iNOS was analyzed before and after antifungal treatment. A difference in the expression within the epithelium was observed. Distinct iNOS staining in the basal cell layers of the epithelium was significantly more common in patients during acute infection (70%) than in controls (20%) (p = 0.034; Figure 3 ). After treatment the staining in the basal cell layers was still present more often in the patients (67%) than in the controls (20%) (p = 0.022). For the general iNOS staining in the epithelium, no differences were observed between patients before and after treatment and controls (Figure 4) . No correlations were found between NO levels and iNOS staining.
At the first visit, patients had various symptoms associated with vulvovaginal Candida infection. A majority had more than one symptom and clinical finding. After treatment the symptom and examination scores were significantly decreased (p < 0.001; Table 2 ). According to the inclusion criteria, all patients had C. albicans in culture before treatment. At the second visit, C. albicans was still identified in cultures in four patients, although they only had minor clinical symptoms. Hyphae in wet mount were observed in six patients after completed treatment. Among those, one patient had C. albicans in culture and symptoms of pruritus. Interestingly, in five of the controls hyphae were observed in wet mount but neither culture or clinical examination showed any signs of infection (Table 2) .
There was a positive correlation before treatment between vaginal NO levels and examination score (r s = 0.677; p < 0.001) and symptom score (r s = 0.644; p < 0.001). After treatment when the NO levels had decreased, no correlations to the examination score (r s = 0.083; ns) or symptom score (r s = 0.236; ns) remained.
Discussion
In the current study we demonstrate a strong inflammatory response in the vaginal mucosa during relapse of Nitric oxide is a marker of inflammation and is part of the nonspecific host defense (22) . The immuno-histochemical results demonstrating iNOS expression in the mucosa, suggest that the NO measured in the vagina probably derives from epithelial iNOS. This is supported by the pronounced inflammatory response in the vaginal mucosa during vulvovaginal candidiasis with erythema, edema and discharge. The distinct staining of iNOS in the epithelial basal membrane has not been described before and is an interesting finding. Even though no correlations were found between NO levels and general iNOS staining, this may still reflect an increased expression of iNOS in patients corresponding to the higher NO levels before and after treatment compared with controls. Other studies investigating chronic inflammatory conditions have reported that mucosal iNOS is located in the upper part of the epithelium facing the lumen of various hollow organs (23) , which was also seen in our sections. Another possible origin of increased NO that could have interfered with our results are other cervical and vaginal infections; these have previously been reported in a study including patients with unspecific vaginitis (19) . For that reason we made a great effort to exclude other infections in our participants.
The role of NO in the vaginal lumen during acute infection is not understood and it is yet unknown whether increased levels of NO in the vagina are beneficial or harmful for the tissue. High concentrations of NO are normally found in the nasal airways without causing tissue damage (23) . However, NO is known to have a dual action and may induce impairment of host cells. Damaging effects of NO likely occur to a large extent through its reaction products, for example following reaction of NO with oxygen radicals. During active inflammation, patients with inflammatory bowel disease (18) had median NO levels in rectum that were 10 times higher than our findings in RVVC. On the other hand, reported NO levels in non-infectious cystitis, asthma and unspecific vaginitis were similar to our results (17, 19, 24) . In bacterial infections such as cystitis and pelvic inflammatory disease, the NO levels were also in accordance with our results (24, 25) .
The method for NO measurement using the catheter balloon in the vagina was first described by Sioutas et al. (19) . The same group later on evaluated the method in the uterine cavity (26) , showing that 2 min incubation of the balloon may be sufficient time to analyze the NO levels and that the method is feasible and well tolerated. The absolute levels of measured NO vary greatly depending on the technique used for measurement and may not necessarily exactly reflect the concentrations found in the mucosa. In a study by Babula et al. (27) , the concentrations of the NO metabolites nitrite and nitrate were determined in women with RVVC during an episode of acute culture-verified infection. Contrary to our results, lower concentrations of NO metabolites were found together with an increased concentration of interleukin-4, a cytokine known to have anti-Candida activity through inhibition by macrophagederived NO (27) . A confounding factor when measuring NO metabolites as opposed to actual NO gas, is that these markers are affected by a number of other factors, including diet and the presence of commensal bacteria (28) . Bacteria can both generate and consume nitrate and nitrite, thereby possibly influencing the results based on measurements of these markers (29) .
We chose to treat the patients with oral fluconazole for six weeks for study purposes and in accordance with previous Swedish guidelines. After treatment, the vaginal NO levels were markedly decreased but they were still significantly higher than the levels in the healthy control subjects. The finding of higher NO levels in culture-free patients after treatment, might be explained by a persisting mucosal inflammatory process that needs more time to heal completely. After treatment, four patients still had positive culture for C. albicans and another five had visible hyphae. Culture is regarded as a more reliable method to detect Candida species (2) and the discrepancy between the two methods might be caused by an overdiagnosis of true hyphae in the microscope. This is also why positive culture for C. albicans was an inclusion criterion. The result of positive cultures after treatment reflects part of the pathogenesis of RVVC with the high recurrence rate of the infections. One important aspect is the length of the treatment period, which probably was too short to eliminate growth of C. albicans in all patients, or that the fluconazole dose was too low. The results illustrate that long-term treatment is needed as previously shown (6) , and that the dose needed to alleviate symptoms should be individualized. Local steroids in combination with anti-fungal treatment might be used during an acute infection, but currently fluconazole is the only recommended long-term treatment. The effect of steroids on vaginal NO has not been studied, but the release of NO in the airways of asthmatic children is reduced after oral steroid therapy (30) .
The understanding of the pathogenesis of RVVC has made progress but there are still areas that need to be investigated. In this study we have demonstrated that NO as a marker of inflammation is associated to symptoms and clinical findings of an acute episode of RVVC. There is no reason to believe that the inflammatory response would be different in sporadic infections of VVC but the susceptibility to recurrent infections might correspond to individual differences in the local immune response for clearing the infection or to virulent factors of the pathogenic Candida strains. From a clinical point of view, a possible reduction of the inflammatory response during RVVC might be of great importance. RVVC is a known risk factor for developing vulvar pain and dyspareunia and it is suggested that the repeated inflammation causes hypersensitivity and hyperinnervation of the vulvovaginal mucosa (3). A complementary treatment target in the future could be to find long-term methods to reduce the inflammatory tissue response in patients with RVVC, similar to chronic inflammatory conditions where the alleviation of inflammation and symptoms has priority over cure.
